# Evaluation of 2 Oral Doses of PG-760564 in Rheumatoid Arthritis (RA) Patients Receiving Methotrexate

> **NCT00369928** · PHASE2 · COMPLETED · sponsor: **Procter and Gamble** · enrollment: 254 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** PG-760564
- **DRUG:** Placebo dose
- **DRUG:** PG-760564

## Key facts

- **NCT ID:** NCT00369928
- **Lead sponsor:** Procter and Gamble
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 254 (ACTUAL)
- **Last updated:** 2011-09-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00369928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00369928, "Evaluation of 2 Oral Doses of PG-760564 in Rheumatoid Arthritis (RA) Patients Receiving Methotrexate". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00369928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*